| DORDAVIPRONE HYDROCHLORIDE | None | ||
| 125MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). | |||
|
Yes
| |||
| MODEYSO | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
|---|---|---|---|---|---|---|---|
| *** ********* | |||||||
| *-******-**-(*-************)-*,*,*,*,*,**-****************[*,*-*]******[*,*-*]*********-*(**)-***, ***** ******* *** ******* ** ***** *** **** ** *********** ******* | ***** ******** ***** **** ********* ** ****** *** ***** ***** ** ** ********** ******* | *********** *** ******* | *********** *** ******* | *-******-*-(*-************)-*,*,*,*,*,*-**************** [*,*-*]******[*,*-*]*********-*(**)-***, ******* *******, *** ***** ******* *** ******* *** ***** *** ** ******* | *********** *** ******* | ***** ******** ***** **** ********* ** ****** *** ***** ***** ** ** ********** ******* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|